📰 Key Statistics News
Page 39 - Key Statistics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Key Statistics. Real-time updates on events, politics, business and more.
July 12, 2023
Mobile Robot Charging Station Market Projected for 15.9% CAGR Surge, Anticipated to Reach USD 28.5 Million by 2032
July 4, 2023
/PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop...
June 14, 2023
MONTHLY FACTSHEET • 31 MAY 2023 Monthly Factsheet HOW WE INVEST ... | June 14, 2023
June 12, 2023
Decision based on CAPItello-291 Phase III trial results which showed the combination reduced the risk of disease progression or death by 40% vs. FASLODEX alone Potential first-in-class AKT... | June 12, 2023
June 9, 2023
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and the Blood and Marrow Transplant Clinical Trials Network (BMT...
June 7, 2023
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA®...
June 6, 2023
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an expert review article in Blood Advances examining the development path and...
May 24, 2023
Highlights Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy...
May 24, 2023
Highlights Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy with 67Cu SAR-bisPSMA at the lowest dose level of 4GBq. No dose limiting toxicities (DLTs) have been reported in cohort 1. The Safety Review Committee (SRC) has recommended that the trial continues to cohort 2. Recruitment has opened at clinical sites in the United States (US) at the cohort 2 dose level of 8GBq and patients are currently in ...
May 24, 2023
Highlights SYDNEY, May 24, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the completion of cohort 1 and advancement to cohort 2 in the therapeutic phase of its Phase I/II...